Cargando…
Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis
Background: This study was initially designed to examine whether oxaliplatin-based regimen was superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced gastric cancer (GC). Methods: Literature in EMBASE, PUBMED, Cochrane Central Register of Controlled Trials (C...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547983/ https://www.ncbi.nlm.nih.gov/pubmed/31205551 http://dx.doi.org/10.7150/jca.28896 |
_version_ | 1783423779987259392 |
---|---|
author | Zhang, Fei Zhang, Yiyin Jia, Zhenya Wu, Hongyang Gu, Kangsheng |
author_facet | Zhang, Fei Zhang, Yiyin Jia, Zhenya Wu, Hongyang Gu, Kangsheng |
author_sort | Zhang, Fei |
collection | PubMed |
description | Background: This study was initially designed to examine whether oxaliplatin-based regimen was superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced gastric cancer (GC). Methods: Literature in EMBASE, PUBMED, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) was searched. Only phase II or III randomized controlled trials (RCTs) comparing the effectiveness and safety between oxaliplatin-based and cisplatin-based regimens as first-line treatment for advanced GC were selected. Odds ratios (ORs) with 95% confidence intervals (CIs) were reported. The primary endpoints were complete remission rate (CRR), partial remission rate (PRR), objective response rate (ORR), and disease control rate (DCR). The second endpoint was the toxicity response. Results: 2,140 patients from six phase II or III RCTs were included. Compared to cisplatin-based therapy, subjects who received oxaliplatin-based treatment had significantly higher PRR (OR: 1.25, 95%CI: 1.05-1.48, P=0.01, I(2)=0%), ORR (OR: 1.21, 95%CI: 1.02-1.44, P=0.03, I(2)=0%) and DCR (OR: 1.76, 95%CI: 1.31-2.38, P=0.0002, I(2)=25%), but not CRR (OR: 0.70, 95%CI: 0.37-1.31, P=0.27, I(2)=0%). In addition, oxaliplatin-based therapy significantly decreased all grades of leukopenia, neutropenia, anemia, febrile neutropenia, nausea, stomatitis, creatinine elevation and thromboembolism, as well as grades 3-4 of leukopenia, neutropenia, anemia and febrile neutropenia than cisplatin-based regimen. However, oxaliplatin-based treatment strikingly increased the risk of thrombocytopenia, sensory neuropathy, diarrhea, fatigue and liver dysfunction. Conclusions: Oxaliplatin-based regimen is superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced GC, and is associated with less toxicity and better tolerability. |
format | Online Article Text |
id | pubmed-6547983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-65479832019-06-14 Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis Zhang, Fei Zhang, Yiyin Jia, Zhenya Wu, Hongyang Gu, Kangsheng J Cancer Research Paper Background: This study was initially designed to examine whether oxaliplatin-based regimen was superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced gastric cancer (GC). Methods: Literature in EMBASE, PUBMED, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) was searched. Only phase II or III randomized controlled trials (RCTs) comparing the effectiveness and safety between oxaliplatin-based and cisplatin-based regimens as first-line treatment for advanced GC were selected. Odds ratios (ORs) with 95% confidence intervals (CIs) were reported. The primary endpoints were complete remission rate (CRR), partial remission rate (PRR), objective response rate (ORR), and disease control rate (DCR). The second endpoint was the toxicity response. Results: 2,140 patients from six phase II or III RCTs were included. Compared to cisplatin-based therapy, subjects who received oxaliplatin-based treatment had significantly higher PRR (OR: 1.25, 95%CI: 1.05-1.48, P=0.01, I(2)=0%), ORR (OR: 1.21, 95%CI: 1.02-1.44, P=0.03, I(2)=0%) and DCR (OR: 1.76, 95%CI: 1.31-2.38, P=0.0002, I(2)=25%), but not CRR (OR: 0.70, 95%CI: 0.37-1.31, P=0.27, I(2)=0%). In addition, oxaliplatin-based therapy significantly decreased all grades of leukopenia, neutropenia, anemia, febrile neutropenia, nausea, stomatitis, creatinine elevation and thromboembolism, as well as grades 3-4 of leukopenia, neutropenia, anemia and febrile neutropenia than cisplatin-based regimen. However, oxaliplatin-based treatment strikingly increased the risk of thrombocytopenia, sensory neuropathy, diarrhea, fatigue and liver dysfunction. Conclusions: Oxaliplatin-based regimen is superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced GC, and is associated with less toxicity and better tolerability. Ivyspring International Publisher 2019-04-25 /pmc/articles/PMC6547983/ /pubmed/31205551 http://dx.doi.org/10.7150/jca.28896 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Zhang, Fei Zhang, Yiyin Jia, Zhenya Wu, Hongyang Gu, Kangsheng Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis |
title | Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis |
title_full | Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis |
title_fullStr | Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis |
title_full_unstemmed | Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis |
title_short | Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis |
title_sort | oxaliplatin-based regimen is superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced gastric cancer: a meta-analysis |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547983/ https://www.ncbi.nlm.nih.gov/pubmed/31205551 http://dx.doi.org/10.7150/jca.28896 |
work_keys_str_mv | AT zhangfei oxaliplatinbasedregimenissuperiortocisplatinbasedregimenintumourremissionasfirstlinechemotherapyforadvancedgastriccancerametaanalysis AT zhangyiyin oxaliplatinbasedregimenissuperiortocisplatinbasedregimenintumourremissionasfirstlinechemotherapyforadvancedgastriccancerametaanalysis AT jiazhenya oxaliplatinbasedregimenissuperiortocisplatinbasedregimenintumourremissionasfirstlinechemotherapyforadvancedgastriccancerametaanalysis AT wuhongyang oxaliplatinbasedregimenissuperiortocisplatinbasedregimenintumourremissionasfirstlinechemotherapyforadvancedgastriccancerametaanalysis AT gukangsheng oxaliplatinbasedregimenissuperiortocisplatinbasedregimenintumourremissionasfirstlinechemotherapyforadvancedgastriccancerametaanalysis |